![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Over-expression of p21 ras-related protein was determined in the plasma by immunoblotting and in the tissue by immuno-histochemistry in a cohort of patients undergoing colonoscopy. In the plasma samples, p21 ras over-expression was detected in: 9% (4/47) of normal controls; 21% (13/61) of individuals with normal colonoscopies but with a prior history of colonic neoplasia; 12% (4/33) of small adenoma patients, 29% (6/21) of large adenoma patients; 63% (5/8) of carcinoma-in-adenoma patients; 50% (2/4) of Dukes' A carcinoma patients; and 20% (2/10) of Dukes' B-D carcinoma patients. In the tissue samples, p21 ras over-expression was detected in: 25% (2/8) of small adenoma patients; 44% (4/9) of large adenoma patients; 100% (4/4) of carcinoma-in-adenoma patients; and 33% (1/3) of Dukes' B-C carcinoma patients. For matched plasma-tissue pairs, there was a statistically significant correlation for p21 ras over-expression (R = 0.47, p = 0.02).